By targeting the underlying type 2 inflammation, which happens to be the critical driver for bullous pemphigoid, Dupixent has been categorized as the first investigational biologic to demonstrate ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Dupixent approved as the first-ever biologic ... including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... affects older people in the 60 to 80 age bracket. Dupixent (dupilumab) achieved a five-fold greater sustained ...

Dupixent for the treatment of COPD has been approved in ... including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are ...

Dupixent for the treatment of COPD has been ... including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently ...

such as Dupixent for the treatment of adults with chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron’s ...